Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4+ T Cells to the Dengue Virus Envelope Protein Domain III

Products Related to West NileDengueMalariaT.BChikungunyaSarsZika

Product# 30070: Recombinant Dengue D2 Envelope Protein (E.coli)    

Product# 30170: Recombinant Dengue Antigen D2 Envelope Protein (Baculo) 

Product# 30030: Recombinant Dengue D3 NS1 (E.coli)





Dengue fever has become a global threat, causing millions of infections every year. An effective vaccine against all four serotypes of dengue virus (DENV) has not been developed yet. Among the different vaccination strategies available today, DNA vaccines are safe and practical, but currently induce relatively weak immune responses in humans. In order to improve immunogenicity, antigens may be targeted to dendritic cells (DCs), the main antigen presenting cells and orchestrators of the adaptive immune response, inducing T and B cell activation. It was previously shown that a DNA vaccine encoding a fusion protein comprised of an antigen and a single-chain Fv antibody (scFv) specific for the DC endocytic receptor DEC205 induced strong immune responses to the targeted antigen. In this work, we evaluate this strategy to improve the immunogenicity of dengue virus (DENV) proteins. Plasmids encoding the scFv αDEC205, or an isotype control (scFv ISO), fused to the DENV2 envelope protein domain III (EDIII) were generated, and EDIII specific immune responses were evaluated in immunized mice. BALB/c mice were intramuscularly (i.m.) immunized three times with plasmid DNAs encoding either scDEC-EDIII or scISO-EDIII followed by electroporation. Analyses of the antibody responses indicated that EDIII fusion with scFv targeting the DEC205 receptor significantly enhanced serum anti-EDIII IgG titers that inhibited DENV2 infection. Similarly, mice immunized with the scDEC-EDIII plasmid developed a robust CD4+ T cell response to the targeted antigen, allowing the identification of two linear epitopes recognized by the BALB/c haplotype. Taken together, these results indicate that targeting DENV2 EDIII protein to DCs using a DNA vaccine encoding the scFv αDEC205 improves both antibody and CD4+ T cell responses. This strategy opens perspectives for the use of DNA vaccines that encode antigens targeted to DCs as a strategy to increase immunogenicity.

Keywords: dengue fever, dendritic cells, envelope protein domain III, single-chain Fv antibody, DNA vaccine


Dengue virus (DENV) is the causative agent of dengue fever, an infection that has become a serious public health issue. In the last decades, the alarming increase in the number of cases [50–100 million per year, (1)] and also the increase in the incidence of more severe clinical forms of the disease (like dengue hemorrhagic fever, DHF or dengue shock syndrome, DSS) led the World Health Organization to prioritize the development of a vaccine against dengue (2). DENV is transmitted to humans by the bite of mosquitoes of the genus Aedes (such as Aedes aegypti and Aedes albopictus) infected with one of the four virus serotypes (DENV 1–4) (3).

The virus genome is translated into a polyprotein which is processed by virus and host proteases to produce three proteins that make up the viral particle: capsid (C), pre-membrane/membrane (prM/M) and envelope (E), and seven other non-structural proteins, NS1, NS2a, NS2b, NS3a, NS4a, NS4b, and NS5 (3). The E protein plays an important role in the protective immunity against DENV as it contains the majority of epitopes that elicit neutralizing antibodies (46). This protein can be divided into three domains: the central domain (EDI), the domain responsible for dimerization containing the fusion peptide (EDII), and the domain that binds to the surface cell receptor (EDIII) (2). EDIII has been extensively used in vaccine development for its ability to induce antibodies able to block DENV infection (79). In addition to neutralizing antibodies, T cell responses also play a relevant role in the development of protection. T cells limit the spread of viral infection because they kill infected cells and secrete pro-inflammatory cytokines (1011). IFNγ-secreting Th1 and CX3CR1+ cytotoxic CD4+ T cells are also associated with protection (1213).

Dendritic cells (DCs) are central for immunity induction, activating both T and B cells. These cells are excellent antigen presenting cells (APCs) because of their ability to acquire different antigens (either by pinocytosis, endocytosis, or phagocytosis), when compared to other cell types such as macrophages and B cells (14). To accomplish their role as APCs, DCs express a large number of extra and intercellular receptors that are responsible for their ability to “sense” the environment. When they encounter an antigen in the context of infection/inflammation, DCs undergo a maturation process that results in the up-regulation of co-stimulatory and MHCII molecules, and increases their ability to present antigens in the context of MHC I and II (15).

The last decades have proven to be extremely prolific for the study of DC biology and function, as different DC subsets were identified both in humans and in mice (16). Each subset is normally characterized by the expression of different surface markers. The DEC205 is an endocytic C-type lectin receptor expressed by murine and human DCs in different organs (1720) that uptakes antigens and directs them to MHCII rich late endosomes, increasing antigen presentation to CD4+ T cells (21). In mice, DEC205+ DCs are resident in the T cell zone of lymphoid organs, and also express the CD8α marker (22). The DEC205+CD8α+ DCs were involved in the uptake of dying cells, and in the resistance to some viral infections (2325). Antigens derived from different pathogens have been targeted to DEC205+CD8α+ DCs using chimeric anti-DEC205 monoclonal antibodies (mAbs) genetically fused to them, administered in the presence of a DC maturation stimulus (2634).

The use of chimeric mAbs to target antigens to different endocytic receptors has become more spread, and this concept was employed in the development of more effective DNA vaccines. These vaccines are usually safe, cheap, easy to produce but may fail to induce strong immune responses, especially in humans (35). An improvement in the immune response was obtained after antigen targeting to the DEC205+ DCs using DNA vaccines consisting of plasmids encoding a single chain variable fragment (scFv) fused to the antigen of interest (3641). However, other groups have shown that antigen targeting to DEC205+ DCs using DNA vaccines was also able to induce immune tolerance to the antigen of interest and consequently protect against experimental allergic encephalomyelitis (42).

In this work, we generated a DNA vaccine encoding the anti-DEC205 scFv fused to DENV2 EDIII (pscDEC-EDIII). Vaccine administration by intramuscular immunization followed by electroporation elicited high titers of anti-EDIII antibodies in mice immunized with pscDEC-EDIII capable of blocking DENV2 infection in VERO cells. In addition, EDIII targeting to DEC205+ DCs within the context of a DNA vaccine elicited specific CD4+ T cell proliferation and pro-inflammatory cytokine production.

Go to:

Materials and Methods

Plasmid Generation

Constructions of the pcDNA3 scDEC-OVA and scISO-OVA plasmids were described previously (37). We digested the DNA fragment encoding ovalbumin (OVA) with the restriction enzymes NotI and XbaI (New England Biolabs) and purified the open vectors with the “PureLink Quick Plasmid DNA” kit (Invitrogen). The sequence corresponding to the ectodomain of the DENV2 envelope protein (HQ026763, lineage DENV-2/BR0690/RJ/2008) was synthetized and cloned into the pUC57 plasmid (Genscript USA Inc.). We amplified the EDIII sequence (aa 297–394) with the primers sense 5′ GGCGGCCGCATGTCCTACTCTATGTGCAC 3′ and anti-sense 5′ TCTAGATCAGTGATGGTGATGGTGATGTTTCTTAAACCAATTCAGCTTC 3′ with the Phusion High Fidelity DNA Polymerase (New England Biolabs) according to the manufacturer's instructions. The anti-sense primer was also designed to insert a 6 × His-tag at the end of the sequence. The PCR product was cloned into the pJET1.2/blunt vector (Thermo Scientific) and digested with the restriction enzymes NotI and XbaI (New England Biolabs). The digestion product was purified with the “PureLink Quick Plasmid DNA” kit (Invitrogen) and cloned in frame with the open reading frames of scDEC and scISO in the pcDNA3 vectors using the T4 DNA ligase enzyme (New England Biolabs). The final vectors, named pscDEC-EDIII and pscISO-EDIII were sequenced to confirm the presence of the EDIII sequence in frame with the antibody sequences. We transformed the plasmids into DH5α bacteria and purified the DNA in large scale using the “EndoFree Plasmid Maxi Kit” (QIAGEN) for subsequently transfection of human embryonic kidney (HEK) 293T cells and mice immunization.

HEK 293T Transient Transfection

The transfection of HEK293T cells was performed as described previously (30). After 5 days in culture, the supernatants of cultures transfected with pscDEC-EDIII or pscISO-EDIII were collected, centrifuged at 1,000 × g for 30 min and filtered in 0.22 μM filters (Corning). The samples were concentrated in a dialysis membrane surrounded by sucrose and dialyzed twice in PBS for 4 h at 4°C.

Western Blotting

The scDEC-EDIII or scISO-EDIII containing samples were sorted in a 12% SDS-PAGE gel under reducing conditions. The proteins were transferred to a nitrocellulose membrane (GE Healthcare) and the membrane was blocked overnight at 4°C with PBS containing 0.05% Tween 20 (PBS-T 0.05%), 2.5% BSA and 5% non-fat milk. After three 5-min washes with PBS-T 0.05%, the membrane was incubated with 6x-HIS tag monoclonal antibody (1:5,000; Thermo Fisher Scientific) at room temperature (rt) for 2 h. Next, the membrane was incubated with goat anti-mouse total IgG-HRP antibody (1:2,000; Jackson ImmunoResearch Laboratories) for 2 h at rt and developed using quimioluminescence (ECL kit, GE Healthcare).

CHO-DEC Binding Assay

Transgenic CHO cells stably expressing the mouse DEC205 receptor (kindly provided by Dr. Michel Nussenzweig, The Rockefeller University, New York) were used for the binding assays. One hundred thousand cells were incubated with 4, 2, or 1 μg/mL of the scDEC-EDIII or scISO-EDIII scFvs for 40 min on ice. After two washes with FACS buffer (2% fetal bovine serum in PBS), cells were incubated with the 6x-HIS tag monoclonal antibody (1:5,000; Thermo Fisher Scientific) for 20 min on ice. The cells were washed two times again with FACS buffer and incubated with the anti-mouse IgG-Alexa488 antibody (1:2,000; Life technologies). After another round of washes, the cells were analyzed by flow cytometry and 20,000 events were acquired in the FACSCalibur™ flow cytometer (BD Biosciences).

Mice and Immunization

Six- to eight-weeks-old male BALB/c mice were bred at the Isogenic Mouse Facility of the Parasitology Department, University of São Paulo, Brazil. This study was carried out in accordance with the recommendations of the Federal Law 11.794 (2008), the Guide for the Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation (CONCEA) and the ARRIVE guidelines. The Institutional Animal Care and Use Committee (IACUC) of the University of São Paulo approved the protocol under the following number: 36/2016. Groups of eight animals were immunized with 100 μg of pscDEC-EDIII or pscISO-EDIII diluted in saline (0.9% NaCl). A control group consisting of 4 animals was injected with saline alone. Briefly, the animals were anesthetized by intraperitoneal (i.p) injection of a mixture of Ketamine and Xylazine (100 and 10 mg/kg, respectively). Next, the skin over the hind leg was sterilized with ethanol and the injections were carried out intramuscularly (i.m.) in the anterior tibial muscle of the mice followed immediately by electroporation. For the electroporation, two 130 V pulses with 1 ms duration and four 70 V pulses with 50 ms duration were applied with the CUY560-5-0.5 electrode using the NEPA21 Super Electroporator (Nepa Gene Co., Ltd.). The interval between each pulse was 450 ms. Three doses were administered in 2-week intervals. Animals were euthanized 2 weeks after the last dose, their sera were collected via cardiac puncture and the spleens were removed for subsequent analysis.


We used sera collected from the different immunization groups for the detection of EDIII-specific antibodies by ELISA. High binding ELISA plates (Costar) were coated overnight at rt with 100 ng/well of the recombinant EDIII protein (43) diluted in PBS. In the following day, the plates were washed three times with PBS containing 0.02% Tween 20 (PBS-T 0.02%) and then blocked with PBS-T 0.02%, 1% BSA, and 5% non-fat milk for 1 h at rt. After three washes, serum samples were serially diluted in PBS-T 0.02%, 0.25% BSA, and 5% non-fat milk and incubated for 2 h at rt. Goat anti-mouse IgG antibody conjugated with horseradish peroxidase (HRP) (1:2,000; Jackson ImmunoResearch Laboratories) or HRP conjugated subclass-specific anti-mouse IgG (1:2,000; SouthernBiotech) were used as secondary antibodies, and plates were incubated for 2 h at rt. ELISA was developed with ortho-phenylenediaminedihydrochloride (Sigma) and H2O2 diluted in phosphate–citrate buffer, pH 4.7. The reaction was stopped with 4N H2SO4 and the OD490 was measured in a microplate reader (Biotek). Titers represent the highest serum dilution showing an OD490 > 0.1 normalized in a log10 scale. The IgG1/IgG2a ratio was calculated by dividing the mean values of the highest serum dilution obtained for IgG1 by the mean value of the highest serum dilution obtained for IgG2a without normalization. To determine the avidity of the antibodies, we performed an extra step before adding the secondary antibody. Fixed dilutions (OD490 = 0.7) of the samples were incubated with 7 M urea or PBS for 5 min. After three washes, the procedure continued exactly as described for the standard ELISA protocol. The avidity index was calculated by the sample's OD490 × 100 in 7 M urea divided by the OD490 in PBS.

Virus Neutralization Assay and Competition Assays

Viral neutralization was assessed via a flow cytometry based assay adapted from (44). VERO cells (1 × 105 cells/well) were cultured in flat-bottomed 96-well plates (Costar) overnight at 37°C and 5% CO2. Sera from immunized mice were heat inactivated at 56°C for 30 min. Two-fold serially diluted sera were incubated with virus particles of the DENV2 NGC strain (MOI of 0.1) for 30 min at 37°C and 5% CO2. The sera/virus mixtures were then incubated with the cells for 1 h at 37°C and 5% CO2. Next, the sera/virus mixtures were removed and DMEM containing 5% fetal bovine serum (FBS) was added to the cells that were then incubated for 24 h at 37°C and 5% CO2. Trypsin was used to detach the cells that were resuspended in DMEM 5% FBS and transferred to V-bottomed 96-well plates. Cells were fixed and stained as described previously (45) using 4G2 (10 μg/mL; mouse anti-flavivirus envelope antibody) as a primary antibody and anti-mouse IgG-Alexa488 (1:2,000; Life technologies) as a secondary antibody. The cells were resuspended in FACS buffer and 20,000 events were acquired in the BD FACSCalibur™ flow cytometer (BD biosciences). The sera effect on virus neutralization was determined in comparison to a control infection with sera derived from mice injected with saline only.

For the competition assay, adapted from (43), a fixed dilution of the sera from the groups (1:20) was incubated with different molar concentrations of the recombinant EDIII protein for 30 min. The sera/protein mixture was then incubated with the DENV2 NGC strain for 30 min and the experiment continued as described above. Neutralization of infection was determined in comparison to a control infection with DENV2 incubated with recombinant EDIII plus sera from saline injected mice.


VERO cells (25 × 103 cells/well) were cultured on glass coverslips inside 24-well plates (Costar) overnight at 37°C and 5% CO2. Infections were performed with MOI of 0.1 with the DENV2 NGC strain for 1 h. After this period, supernatants containing the virus were discarded and the cells were incubated for 24 h in DMEM 5% FBS. Cells were fixed with ice-cold methanol for 5 min and the coverslips were blocked in PBS containing 1% BSA for 1 h at rt. Next, cells were incubated with pooled sera from the different mouse groups, or with the 4G2 mAb (as a positive control), during 1 h at rt, followed by another incubation with anti-mouse IgG-Alexa488 (1:2,000; Life technologies) in the same conditions. Nuclei were labeled with DAPI (1 μg/mL) and the images were acquired in a fluorescence microscope (Leica DMI6000B/AF6000, Buffalo Grove, IL, USA) coupled to a digital camera system (DFC 365 FX, Leica) and processed by the Leica Application Suite X (LAS X).

Splenocyte Isolation

Two weeks after the last vaccine dose, spleens were removed aseptically and processed exactly as previously described (30). Pools (n = 4; two pools per group) of bulk splenocytes were resuspended in R10 [RPMI supplemented with 10% of FBS (GIBCO), 2 mM L-glutamine (GIBCO), 10 mM Hepes (GIBCO), 1 mM sodium pyruvate (GIBCO), 1% vol/vol non-essential aminoacid solution (GIBCO), 1% vol/vol vitamin solution (GIBCO), 20 μg/mL of ciprobacter (Isofarma, Brazil) and 5 × 10−5 M 2-mercaptoetanol (GIBCO)]. Cell viability and concentration were estimated using the Countess™ Automated Cell Counter (Invitrogen).

Peptide Library

A peptide library comprising the DENV 2 E protein (HQ026763, lineage DENV-2/BR0690/RJ/2008) amino acids 161–404 was synthesized by GenScript USA Inc. This library contained 29 overlapping 20-mer peptides that were synthesized with more than 75% purity. Peptides were resuspended in water (10 mg/mL) and stored at −20°C. For in vitro stimulation experiments, peptides were divided into 3 pools as depicted in Table 1.

Table 1

List of peptides derived from the E protein.

Peptide position

Peptide sequence*


Pool number





















































































































Open in a separate window

*Bold shows the EDIII amino acid sequence.


We used the mouse IFN gamma ELISPOT Ready-SET-Go!®; (eBioscience) to detect IFN-γ producing splenocytes. The procedure was performed according to the manufacturer‘s instructions. Briefly, ELISpot plates (MAIPS4510; Millipore) were coated with the capture antibody and incubated overnight at 4°C. The plates were washed twice with PBS and blocked for 1 h with R10 at rt. Splenocytes were incubated in the presence of 2 μg/mL pooled EDIII or EDI/II (negative control) peptides for 20 h at 37°C with 5% CO2. Unpulsed cells were used as controls for each group. After incubation, the plates were washed three times with PBS-T 0.05% and incubated for 2 h at rt with the biotinylated anti-IFN-γ antibody. Following another round of washes, the plates were incubated with avidin-HRP for 45 min at rt. Plates were washed three times with PBS-T 0.05% and the spots were developed with the “AEC substrate set” kit (BD biosciences). We used an automated stereomicroscope (KS ELISPOT, Zeiss, Oberkochem, Germany) to count the number of spots. The formula (# of spots in the pulsed well – # of spots in the unpulsed well) was used to calculate the number of IFN-γ producing cells/106 cells.

Proliferation and Intracellular Staining (ICS)

To analyze T cell proliferation, splenocytes from mice were labeled with carboxyfluoresceinsuccinimidyl ester (CFSE). Briefly, 50 × 106 splenocytes were resuspended in pre-heated PBS and labeled with 1.25 μM of CFSE for 10 min at 37°C. Cells were then washed, resuspended in R10 and 3 × 105 cells/well were incubated at 37°C and 5% CO2 in 96-well round-bottomed plates with 2 μg/mL of pooled EDIII or EDI/II (negative control) peptides. Unpulsed cells were used as controls for each group. After 3 days in culture, cells were restimulated with the same peptide pools plus 2 μg/mL of αCD28. After 1 h incubation at 37°C and 5% CO2, 0.5 μg of Golgi Plug (Brefeldin A, BD Pharmingen) was added per well, and the plate was incubated for 12 h at 37°C and 5% CO2. After the incubation period, the cells were washed with FACS buffer and transferred to V-bottomed 96-well plates. Cells were stained with LIVE/DEAD® dye (Life Technologies) and αCD4-PerCP (clone RM4-5) for 40 min on ice and in the dark. After 4 washes with FACS Buffer, the cells were fixed and permeabilized using the Cytofix/Cytoperm kit (BD Pharmingen) according to the manufacturer's instructions. The cells were then washed three times with PermWash buffer (BD Pharmingen). The intracellular staining was performed using αCD3-APC/Cy7 (clone 145-2C11), αIFNγ-APC (clone XMG1.2), αIL2-PE (clone JES6-5H4), and αTNFα-PE/Cy7 (clone MP6-XT22) for 40 min on ice and in the dark. The cells were washed twice and resuspended in FACS Buffer. All antibodies were purchased from BD Pharmingen. Flow cytometer readings were carried out with 200,000 events acquired in the BD LSRFortessa flow cytometer (BD Biosciences) and analyzed using FlowJo software (version 9.3, Tree Star, San Carlo, CA). The analysis of proliferating (CFSElow) cells producing different combinations of cytokines (IFNγ, IL-2, and TNFα) was performed with the Boolean gating platform (FlowJo Software). The percentages of proliferating or/and cytokine-producing cells were calculated by subtracting the values obtained with unpulsed cells.

Data Analysis

We used the Prism 7 software (GraphPad Software Inc, LA Jolla, CA) for all tests. Statistical differences were considered significant when p ≤ 0.05. One-way ANOVA followed by Tukey's honestly significantly different (HSD) were used for the ELISA data and Two-way ANOVA followed by Bonferroni correction was used for the ELISpot, CFSE and ICS data. The NT50 values for the neutralization assays were determined with the non-linear regression (curve fit) analysis.

Go to:


Production of the Recombinant scFvs

The DENV2 EDIII nucleotide sequence (encoding amino acids 297–394) was cloned in frame into plasmids encoding the variable regions of the heavy and light chains of the anti-DEC205 (clone NLDC145) and the isotype control (clone III/10) as previously described (37). Figure 1A shows a schematic representation of pscDEC-EDIII and pscISO-EDIII that were then used to transfect HEK293T cells. Western blot analyses of concentrated cell culture supernatants confirmed secretion of scDEC-EDIII and scISO-EDIII by transfected cells (~46 kDa, Figure 1B). To demonstrate that scDEC-EDIII retained the capacity to bind to the DEC205 receptor, CHO cells stably expressing the murine DEC205 receptor were incubated with different concentrations of either scDEC-EDIII or scISO-EDIII. Figure 1C shows that only the scDEC-EDIII bound to DEC205 receptor in a concentration dependent manner. Taken together, these results indicate that both scFvs were successfully secreted from transiently transfected cells, and that the scDEC-EDIII preserved its binding capacity to the DEC205 receptor.





Figure 1

Construction and characterization of the plasmids encoding the EDIII antigen genetically fused with scFvs. (A) Map of the plasmid vectors encoding the scFvs fused to the EDIII antigen. The EDIII DNA sequence was cloned in frame with the C-terminal portion of the variable light-chain (VL) after the linker sequence GGSSGGSGGGGSGGGGR. The variable heavy-chain (VH) is connected to the VL via a linker (GGGGS)3. pCMV: Cytomegalovirus promoter; His 6x: polyhistidine tag; BGH pA: bovine growth hormone polyadenylation signal. (B) Western blotting with the supernatant of HEK293T cells transfected with pscDEC-EDIII and pscISO-EDIII. The membrane was incubated with a 6x-HIS tag mAb followed by incubation with goat anti-mouse total IgG-HRP. E protein: DENV2 envelope protein; BSA: bovine serum albumin. Numbers on the side indicate the molecular weight (kDa). (C) Binding of scDEC-EDIII or scISO-EDIII to the DEC205 receptor constitutively expressed by CHO cells. One hundred thousand CHO cells were incubated with 4, 2 or 1 μg/mL of either scFv. Cells were labeled with a 6x-HIS tag mAb followed by incubation with goat anti-mouse IgG-Alexa488. Analysis was performed using the FlowJo software (version 9.3, Tree Star).

In vivo EDIII Targeting to DCs Improves Antibody Responses

Next, we assessed if immunization with pscDEC-EDIII could improve the anti-EDIII antibody response. For that purpose, mice received three doses of each plasmid administered i.m. followed by electroporation (Figure 2A). Twelve days after the administration of the first and second doses, and 14 days after the third dose, mice were bled and the sera were tested individually for reactivity against the recombinant EDIII produced in bacteria. Supplementary Figure 1 shows an increase in anti-EDIII antibody titers in mice immunized with both plasmids, especially after the administration of the third dose. Moreover, the anti-EDIII antibody titers observed in the animals immunized the pscDEC-EDIII were higher than those observed in mice immunized with pscISO-EDIII (Figure 2B). When IgG subclasses present in the sera of immunized mice were analyzed, IgG1, IgG2a, and IgG2b but not IgG3 were detected (Figure 2C). Notably, the IgG1/IgG2a ratio detected in mice immunized with pscDEC-EDIII was approximately 10 × higher (6.62) than the one obtained in mice immunized with pscISO-EDIII (0.60). When antibody avidity was measured, we noticed that it was higher in sera from mice immunized with pscDEC-EDIII than in mice immunized with pscISO-EDIII (Figure 2D). Anti-EDIII antibodies were also tested for binding to the viral E protein by immunofluorescence and, as expected, sera collected from mice immunized with pscDEC-EDIII or pscISO-EDIII reacted with VERO cells previously infected with DENV2 (Figure 2E). The labeling patterns were similar to those observed in infected cells stained with 4G2 mAb that recognizes the E protein of Flaviviruses. These results indicate that there are differences in the magnitude, and in the quality of anti-EDIII antibodies raised after immunization with pscDEC-EDIII or pscISO-EDIII.



Open in a separate window

Figure 2

Anti-EDIII antibody responses in mice immunized with pscDEC-EDIII and pscISO-EDIII. (A) Immunization regimen. Groups of BALB/c mice were immunized i.m. with the plasmids followed by electroporation. Three doses were given in 2-weeks intervals. (B) Total anti-EDIII IgG antibody titers and (C) IgG subclasses, 14 days after the administration of the third vaccine dose (n = 24; pscDEC-EDIII and pscISO-EDIII and n = 12; Saline, from three independent experiments). ELISAs were performed using recombinant EDIII as antigen and developed using a goat anti-mouse total or subclass specific IgG-HRP antibodies. Graphs show the antibody titers in normalized log10 scale. (D) Avidity of the anti-EDIII antibodies. Fixed dilutions of the pooled group samples were incubated with 7 M urea or PBS. The avidity index was calculated by the sample's OD490 × 100 in 7M urea divided by the OD490 in PBS. Symbols represent individual mice, columns, and bars represent the mean and SD for each group. Data were analyzed by a one-way ANOVA followed by the post-test HSD Tukey (B) or by unpaired t-test (D)P-value indicators **** refer to p < 0.0001. (E) Recognition of the DENV2 virus by the sera from mice immunized with pscDEC-EDIII and pscISO-EDIII. VERO cells were infected with DENV2 NGC strain or mock (medium). Cells were fixed with methanol and incubated with the sera from mice immunized with either scFv. The virus/sera and nuclei were labeled with the anti-mouse IgG-Alexa488 (green) and DAPI (blue), respectively. The 4G2 mAb was used as a control. Results shown are representative of two independent experiments. Scale bar, 10 μm.

Anti-EDIII Antibodies Raised in Immunized Mice Inhibit DENV2 Infection

Anti-EDIII antibodies were shown to be effective to block virus entry into eukaryotic cells (794647). We then analyzed if anti-EDIII antibodies present in the sera of immunized mice were able to block DENV2 infection. Figure 3A shows that antibodies raised in mice immunized with both scFvs plasmids inhibited virus entry with the same efficiency and in a dilution dependent manner. The 50% neutralization titers (NT50) were also similar for sera derived from pscDEC-EDIII (1.66) or from pscISO-EDIII (1.69) immunized mice. To verify if the anti-EDIII antibodies were able to block DENV2 infectivity by binding to EDIII, we performed a competition assay using different concentrations of recombinant EDIII and a fixed serum dilution. Sera derived from mice immunized with pscDEC-EDIII, or pscISO-EDIII were then incubated with increasing amounts of EDIII. We observed a reduction in the sera capacity to inhibit DENV infection as the amount of EDIII was increased (Figure 3B). Of note, although we noticed a difference in the slope of the curves between the two groups, no statistical significance was observed, indicating that the anti-EDIII antibodies induced in both groups bound equally well to recombinant EDIII.




Open in a separate window

Figure 3

Antibodies from mice immunized with pscDEC-EDIII and pscISO-EDIII partially inhibit DENV infection by binding to EDIII. (A) Neutralization in VERO cells. Pooled sera from mice immunized as described in Figure 2 were heat inactivated at 56°C for 30 min. Two-fold serially diluted sera were incubated with the DENV2 particles for 30 min at 37°C and 5% CO2. The sera/virus mixture was then incubated with the cells for 1 h at 37°C and 5% CO2. The cultures supernatant was replaced by DMEM 5% FBS followed by another incubation at the same conditions for 24 h. Cells were stained with the 4G2 (mouse anti-flavivirus envelope antibody) and anti-mouse IgG-Alexa488. The neutralization of infection was determined in comparison to a control infection. Results are represented by means and SEM from pooled data of four independent experiments. (B) Competition assay with the recombinant EDIII protein. A fixed dilution (1:20) of sera was incubated with increasing molar concentrations of EDIII protein prior to incubation with the virus. The cells were resuspended in FACS buffer and 20,000 events were acquired in the BD FACSCalibur™ (BD biosciences) flow cytometer. The neutralization of infection was determined in comparison to a control infection with sera derived from mice injected with saline. Data were analyzed by a two-way ANOVA for repetitive measures followed by Sidak's multiple comparisons test. ns = not-significant. Representative of three independent experiments.

These results indicate that immunization with a DC targeted DNA vaccine was able to elicit higher anti-EDIII antibody titers with higher avidity. However, their blocking capacity did not differ from the blocking capacity of anti-EDIII antibodies induced by the vaccine that did not target DCs.

DC-Targeted DNA Vaccine Elicits Specific IFNγ Production and CD4+ T Cell Proliferation

We also investigated if EDIII targeting to DCs would impact cellular immune responses, particularly CD4+ T cells. Splenocytes harvested 14 days after the administration of the last immunization dose were incubated with three peptide pools containing peptides derived from a library comprising EDI/II and EDIII 20-mer overlapping peptides (Table 1). Pool 1 contained 10 peptides restricted to EDI/II domains (not present in the EDIII sequence encoded by the DNA vaccine plasmids), pool 2 contained five peptides derived from EDI/II and five peptides derived from EDIII sequence, and pool 3 contained nine peptides derived from EDIII amino acid sequence. All three pools were used to stimulate splenocytes from mice immunized with pscDEC-EDIII, pscISO-EDIII or saline. ELISpot assays showed that the number of IFNγ-producing splenocytes derived from mice immunized with pscDEC-EDIII was higher than that observed in mice immunized with the isotype control DNA vaccine or saline (Figure 4A). In addition, the response was mainly directed to a peptide(s) contained in pool 3 (Figure 4A). There was also a statistically significant difference in the number of IFNγ-expressing cells derived from mice immunized with pscDEC-EDIII after stimulation with peptide pool 2. This result suggests that pools 2 and 3 contain peptides able to bind to the BALB/c H-2Kd haplotype. When CD4+ T cell proliferation (representative gating strategy shown in Supplementary Figure 2, CFSElow panel) was analyzed, we also detected a higher frequency of CD3+CD4+CFSElow cells in the DC-targeted DNA vaccine group when compared to the groups immunized with the isotype control plasmid or saline (Figure 4B). Similarly to the previous experiment, the highest frequency of proliferation was directed against pool 3. As expected, pool 1 (comprising unrelated peptides derived from EDI/II domain) elicited a lower response in mice immunized with scFv plasmids that was not different from the response induced in animals that received saline.



Figure 4

Vaccination with pscDEC-EDIII induces IFNγ production and CD4+ T cell proliferation. Groups of mice were immunized as described in Figure 2(A) IFNγ ELISpot. Splenocytes were stimulated with 2 μg/mL of the peptides pools (Table 1). (B) Proliferation of CD3+CD4+ cells measured after CFSE staining. Splenocytes were stained with CFSE and stimulated with the same peptide pools (Table 1). After 3 days in culture, cells were pulsed again with the pools and with the αCD28 mAb. The frequency of cells that lost CFSE was determined by flow cytometry on the 4th day. The gating strategy is shown in Supplementary Figure 2. Columns and bars in both graphs represent the mean and SEM of pooled data from three independent experiments. The amount of spots/proliferation was determined after subtraction of values obtained in non-stimulated samples. Data were analyzed by a two-way ANOVA followed by the post-test HSD Tukey. P-value indicators *, ** and **** refer to p < 0.05, p < 0.01, and p < 0.0001, respectively.

DC-Targeted DNA Vaccine Induces CD4+ T Cells That Proliferate and Produce Pro-Inflammatory Cytokines at the Same Time

We next assessed if CD4+ T cells that proliferated in response to pools 2 and 3 were also able to produce the pro-inflammatory cytokines IFNγ, IL-2, and TNFα (representative gating strategy shown in Supplementary Figure 3). As shown in Figure 5A, the frequency of CD4+ T cells that proliferated and produced IFNγ was higher in animals immunized with pscDEC-EDIII pulsed with pools 2 and 3 when compared to animals that received saline. For pool 3, as observed in the ELISpot assay, the frequency of CD4+CFSElow that produced IFNγ was also higher in mice immunized with pscDEC-EDIII than in the group immunized with pscISO-EDIII. We did not observe significant differences among the groups when we compared the frequency of CD4+CFSElow cells that produced IL-2 (Figure 5B). TNFα production by proliferating CD4+ T cells was also higher in cells derived from pscDEC-EDIII immunized mice, especially when they were incubated with pool 3. A higher response against pool 2 was also observed, but it did not reach statistical significance when compared to the other two groups (Figure 5C).



Open in a separate window

Figure 5

The pscDEC-EDIII vaccine induces pro-inflammatory cytokines in proliferating CD4+ T cells. Groups of mice were immunized as described in Figure 2 and cytokine production was evaluated by intracellular cytokine staining. (A–C) Splenocytes were stimulated with 2 μg/mL of peptide pools (Table 1). After 3 days in culture, the cells were pulsed again with the pools and with the αCD28 mAb. The frequency of CD3+CD4+ cells that produced (A) IFNγ, (B) IL-2 or (C) TNFα within the CFSElow population was determined by flow cytometry on the 4th day. The gating strategy is shown in Supplementary Figure 3. Columns and bars in both graphs represent the mean and SEM of pooled data from three independent experiments. The percentage of CFSElow cells producing cytokines was determined after subtraction of values obtained in non-stimulated samples. Data were analyzed by a two-way ANOVA followed by the post-test HSD Tukey. P-value indicators *, **, *** and **** refer to p < 0.05, p < 0.01, p < 0.001 and p < 0.0001, respectively.

The results in Figure 5 showed that immunization with pscDEC-EDIII induced CD4+ T cells that proliferated and produced three pro-inflammatory cytokines mainly to peptides contained in pools 2 and 3. To explore this response in more detail, we performed a Boolean analysis of the data (representative gating strategy shown in Supplementary Figure 2, CFSElow and cytokine+ panels), and showed that the CD4+CFSElow cells were polyfunctional and able to produce combinations of the tested cytokines. For example, proliferating CD4+ T cells from mice immunized with pscDEC-EDIII produced all three cytokines simultaneously when pulsed with pool 2 (Figure 6A). Despite not statistically significant, we also observed an increase in the frequencies of CD4+ T cells that proliferated and produced IL-2/TNFα, or only IL-2 or TNFα in pscDEC-EDIII immunized animals. The only exception was due to the IFNγ/TNFα double positive cells whose frequency was higher in pscISO-EDIII immunized animals. Similar results were observed in assays using pool 3 (Figure 6B). Mice immunized with pscDEC-EDIII showed a statistically significant increase in the frequency of triple positive CD4+ T cells when compared to the group that received saline. Moreover, the percentage of CD3+CD4+ cells that proliferated and produced only TNFα was statistically higher in mice immunized with pscDEC-EDIII than in those that received pscISO-EDIII or saline. Despite not significant, we observed that animals immunized with pscDEC-EDIII presented a higher frequency of cells positive for IFNγ/TNFα, only IFNγ, or only IL-2 when compared with the other two groups. Taken together, these results indicate that EDIII targeting to DCs using a DNA vaccine was able to elicit a polyfunctional CD4+ T cell response.




Open in a separate window

Figure 6

Boolean analysis of the CD3+CD4+CFSElow cells producing different combinations of IFNγ, IL-2, and TNFα. Groups of mice were immunized as described in Figure 2. Splenocytes were stimulated with 2 μg/mL of peptide pool 2 (A) or 3 (B). After 3 days in culture, cells were pulsed again with the peptide pools and αCD28 mAb. Proliferation and IFNγ, IL-2, and TNFα production were evaluated by CFSE staining and ICS, respectively. The Boolean gating platform was used to analyze all the different possible combinations of CD3+CD4+CFSElow cells expressing each or combinations of the cytokines. The gating strategy is shown in Supplementary Figure 2. Columns and bars in both graphs represent the mean and SEM of pooled data from two independent experiments. The frequencies of CFSElow cells producing cytokines were determined after subtraction of values obtained in non-stimulated samples. Data were analyzed by a two-way ANOVA followed by the post-test HSD Tukey. P-value indicators *, **, and **** refer to p < 0.05, p < 0.01 and p < 0.0001, respectively.

Identification of EDIII-Specific Epitopes Recognized by CD4+ T Cells Elicited in Mice Immunized With pscDEC-EDIII

In order to identify the peptide(s) present in the pools able to specifically activate CD4+ T cell responses in mice immunized with pscDEC-EDIII, we performed an ELISpot assay using individual peptides comprising the complete EDIII sequence plus two control peptides derived from EDI/EDII (EIKITPQSSTTEAELTGYGT and STTEAELTGYGTVTMECSPR). Splenocytes from mice immunized with pscDEC-EDIII were pulsed with each individual peptide and the number of IFNγ producing splenocytes/106 total cells was recorded. Figure 7 indicates that the response was mainly directed to two peptides: MDKLQLKGMSYSMCTGKFKI present in pool 2, and RHVLGRLITVNPIVTEKDSP in pool 3. In addition, we observed that peptide RHVLGRLITVNPIVTEKDSP represented the immunodominant epitope since the response directed to it was almost three times higher than that detected after stimulation with peptide MDKLQLKGMSYSMCTGKFKI.

Figure 7

Two peptides from the EDIII sequence induce IFNγ production. Groups of mice were immunized as described in Figure 2 and an IFNγ ELISpot was performed. Splenocytes from mice immunized with pscDEC-EDIII were stimulated with 2 μg/mL of peptides spanning the entire EDIII sequence. Peptides EIKITPQSSTTEAELTGYGT and STTEAELTGYGTVTMECSPR from EDI/II sequence were used as negative controls. Columns and bars represent the mean and SEM of pooled data from two independent experiments. The number of spots was determined after subtraction of values obtained in non-stimulated samples.

Go to:


Dengue infection has become a major public health concern as the disease outbreaks and complications have increased substantially in the last five decades (48). Since then, the development of a vaccine has become a global health priority. The challenge is enormous as dengue is caused by four different serotypes and a previous immune response against one particular serotype can exacerbate the disease caused by another (8). Different approaches are being evaluated and two vaccines based on live attenuated viruses have reached phase III trials: the CYD-TDV by Sanofi Pasteur and the TV003/TV005 by US National Institutes of Health (49). However, results of the CYD-TDV vaccine indicating that the risk of severe disease could increase in seronegative individuals led WHO to recommend that the vaccine would only be administered in populations with dengue serological prevalence rates above 80% (50). In this way, other approaches are currently being developed.

Antigen targeting to DCs through the use of chimeric mAbs has been a promising strategy to induce either humoral or cellular immune responses against different antigens such as: ovalbumin (2628), Plasmodium yoelii circumsporozoite protein (27), Yersinia pestis LcrV (29), DENV2 non-structural protein 1 (30), Trypanosoma cruzi amastigote surface protein 2 (31), Plasmodium vivax merozoite surface protein 1 (3233), and HIV gag (5152), among others.

However, the production of such mAbs is time consuming and expensive. DNA vaccines, on the other hand, are cheap, safe and easier to produce and purify, but in general are less immunogenic (35). Different approaches have been developed to increase the immunogenicity of DNA vaccines. Among them are the use of electroporation (5354) and the use of plasmids encoding scFv specific for the DEC205 receptor coupled to the antigen of interest.

Although EDIII has been recently used in a DNA immunization strategy (9), in this work we sought to produce a DNA vaccine able to target EDIII from DENV2 to the DEC205+ DCs in vivo. This was accomplished when we fused the sequence of anti-DEC205 scFv to the EDIII, generating the DNA plasmid named pscDEC-EDIII. As a negative control, we also fused the scFv of a control mAb that was not able to bind to DCs (pscISO-EDIII). Interestingly, a similar construct was engineered by Coconi-Linares et al. that expressed a scFvDEC-EDIII in the plant Nicotiana benthamiana (55). In this case, the authors purified the recombinant scFvDEC205-EDIII protein and immunized BALB/c mice in the presence of anti-CD40 and poly (I:C). Their results showed that the scFvDEC205-EDIII was immunogenic, inducing antibodies with neutralization capacity and proliferating T cells. Nonetheless, a more detailed evaluation of the antibody and T cell responses was not performed.

We decided to use the pscDEC-EDIII as a DNA vaccine for its simplicity and potential to induce strong immune responses when administered together with electroporation. Initially we showed that both plasmids (pscDEC-EDIII or its isotype control) were able to drive the production of chimeric scFvs when transfected in HEK293T cells. More importantly, the scFvs were successfully secreted from the cells, indicating availability in the extracellular medium and possible targeting to the DEC205+ DCs. Indeed, scDEC-EDIII showed a concentration dependent binding to the DEC205 receptor. Similar results were obtained with other antigens coupled to the same scFvs (3756).

Once production and DEC205 receptor specific binding were confirmed for scDEC-EDIII, we used scFv plasmids to immunize mice. We showed that the anti-E antibody titers after the administration of three doses were higher in the group immunized with pscDEC-EDIII when compared to the non-targeted control. Others obtained similar results using different antigens like ovalbumin, HIV gag p41 (37), HER2/neu (38), hepatitis B virus (57), human respiratory syncytial virus (40), and botulinum neurotoxin (39). Although the number of doses varied as well as the amount of plasmid DNA, all these studies used electroporation following intramuscular injection. Interestingly, when we analyzed the IgG isotypes elicited by immunization with the scFvs, we noticed that there was a difference in the IgG1/IgG2a ratio in the sera of mice immunized with pscDEC-EDIII or pscISO-EDIII. Although some groups, using different antigens, also obtained similar results (3758), others showed differences when both groups were compared (38). Despite the differences from one study to another, it has become clear that antigen targeting to the DEC205+ DCs modulates the humoral immune response differently than the non-targeted antigen. We also noticed a significant increase in the avidity of the anti-E antibodies raised in mice immunized with pscDEC-EDIII, while antibodies derived from both immunized groups recognized infected cells. A similar recognition pattern was also obtained after intradermal immunization with a DNA plasmid encoding EDIII (9). This result indicated that the EDIII recognized by the mice sera presented a similar conformation when compared to the EDIII present in the viral particle.

EDIII has been previously described as a target for neutralizing antibodies (46475960). We then decided to analyze if sera from scFv immunized animals were able to block virus invasion in vitro. The results showed that sera from mice immunized with pscDEC-EDIII or with pscISO-EDIII blocked DENV2 infection in a dilution dependent manner. This result contrasted with our previous results showing higher titers and avidity in the sera of mice immunized with pscDEC-EDIII. A positive correlation between neutralization capacity and higher avidity to the viral particle was observed previously on dengue-infected patients (61). In contrast, other results using HIV envelope proteins showed that higher avidity not always correlates with neutralization capacity (62). More importantly, when sera from these mice were previously incubated with different amounts of recombinant EDIII, we observed a reversion in the sera capacity to block infection. This result more clearly demonstrated that the antibodies directed to EDIII mediate DENV infection inhibition in this model. Similar results were also obtained when an EDIII recombinant protein was administered in the presence of the heat-labile toxin (LT) or its non-toxic B subunit (43), or when a chimeric protein containing EDIII was administered to monkeys (63).

Our group and others described that antigen targeting to the DEC205+ DCs is a very efficient way of elicit CD4+ T cell responses (273034516465). We then sought to analyze the CD4+ T cell response induced after immunization with plasmids encoding scFvs genetically fused to EDIII. We took advantage of a peptide library comprising overlapping peptides derived from the E protein amino acids 161 to 404. Our data showed that the pscDEC-EDIII immunization induced CD4+ T cells that proliferated when pulsed with peptide pools comprising the EDIII portion of the molecule. An analysis of pro-inflammatory cytokines produced by the animals immunized with pscDEC-EDIII showed a higher frequency of IFNγ and TNFα producing CD4+ T cells when compared to the animals immunized with the isotype control, although IL-2 levels were comparable. Interestingly, there was a difference in the magnitude of the response when splenocytes were pulsed with pools 2 or 3. The frequency of CD4+ T cells that proliferated and produced IFNγ or TNFα was higher after pulse with pool 3, indicating the presence of an immunodominant epitope(s) capable of binding the BALB/c haplotype (H-2Kd). A more detailed analysis showed that pscDEC-EDIII immunization elicited polyfunctional CD4+ T cells producing one, two, or three pro-inflammatory cytokines, even though statistical significance in comparison to the isotype control group was only reached when single TNFα producers were compared. CD4+ T cells producing the same combination of pro-inflammatory cytokines were also observed in animals immunized with scDEC-HIV p41 (37) or with scDEC-HER2 (38). The presence of polyfunctional CD4+ T cells with protective capacity was first described in a mouse model testing a vaccine against Leishmania major (66). After that, many groups set out to investigate if polyfunctional CD4+ T cells could be related with protection in other models. Studies with HIV-1 infected individuals showed that those displaying polyfunctional CD4+ T cells were able to better control disease (6768). In dengue infection, one study showed that CD4+ T cells that produced either IFNγ or IL-2 correlated with protection from secondary virus infection in children (69). Polyfunctional CD4+ T cells were also identified in individuals submitted to a DENV-1 vaccine candidate, although protection against infection was not investigated in this particular study (70).

Worth mentioning is the fact that, in some cases, DNA vaccination with a scFv encoding the scDEC205 fused with an antigen elicited weaker immune responses when compared to the non-targeted controls (565871). The reason for these results is still unclear. In fact, DEC205 targeting using chimeric anti-DEC205 mAbs has been known to induce tolerance if the antigen is delivered in the absence of a DC maturation stimulus (72). However, electroporation facilitates DNA uptake and makes more DNA available for detection by intracellular DNA sensors, thereby activating the production of cytokines as an innate reaction (73). In addition, the plasmid backbone should also be considered. As a mechanistic explanation is still elusive, additional studies are necessary.

Finally, we attempted to map the epitopes responsible for the CD4+ T cell proliferation and cytokine production. When splenocytes from mice immunized with pscDEC-EDIII were pulsed with each individual peptide, we identified two peptides that were probably responsible for the response observed against pools 2 and 3: MDKLQLKGMSYSMCTGKFKI and RHVLGRLITVNPIVTEKDSP, respectively. Peptide RHVLGRLITVNPIVTEKDSP comprises the sequence of peptide RHVLGRLITVNPIVT that was shown to induce IFNγ production when this peptide was used to immunize C57BL/6J mice (74). In addition, the same peptide was also shown to bind to HLA-DRB1*08:02 in patients from Nicaragua (75) and Sri Lanka (76). This result indicates that our immunization strategy may have the potential to induce CD4+ T cells in humans. Peptide MDKLQLKGMSYSMCTGKFKI is contained in the sequence of peptide SGNLLFTGHLKCRLRMDKLQLKGMSYSMCTG, which was previously used to immunize BALB/c mice. Proliferation and release of IL-2 were detected in this case (77). As DEC205 targeting greatly improves CD4+ T cell responses, it is relatively easy to map antigenic peptides. CD4+ T cell epitopes derived from different proteins have been more easily mapped in samples derived from animals submitted to antigen targeting to DCs. CD4+ T cells epitopes were detected in the Plasmodium yoelii circunsporozoite protein (27), in the HIV p24 gag (51), in the Leishmania major LACK antigen (64), in the Yersinia pestis LcrV antigen (65) and in the Trypanosoma cruzi ASP-2 protein (31).

The role of CD4+ T cells in dengue infection is still not very well defined. CD4+ T cells from infected patients were found to have ex vivo specific cytolytic activity against DENV (13). Individuals vaccinated with an experimental live attenuated DENV1 vaccine exhibited CD4+ T cells with cytotoxic and proliferative capacities in vitro (7879). In mouse models, a DNA vaccine encoding the NS1 protein induced protection via CD4+ T cells and antibodies (80). Immunization with a chimeric αDEC205 mAb fused to NS1 was also able to induce CD4+ T cells that contributed for protection (30). Yauch et al. showed that vaccination with CD4+ peptides in an IFN-α/βR−/− mouse model reduced viral loads. Interestingly, CD4+ T cells did not seem to have an impact on antibody neutralization of the virus measured by infection of C6/36 cells (81). Further studies will be needed to address the role of CD4+ T cells in our model.

Although in the literature CD8α+ DCs are described as playing an important role in the uptake of apoptotic cells and in antigen cross-presentation in the context of MHC Class I (8283), we did not detect a robust CD8+ T cell response induced by our scFv DNA vaccines (data not shown). One reason for that might be related to the choice of the EDIII as an antigen, as most CD8+ T cell epitopes are localized on the non-structural proteins, especially NS3 and NS5 (84). Our group has previously demonstrated that NS1 targeting to DCs via DEC205 induced protection partially mediated by CD8+ T cells (30). In addition, studies mapping CD8+ T cell epitopes usually use peptides of no more than 12-15 amino acids. Our peptide library consisted of 20-mers, which might have restricted the identification of CD8+ T cell responses.

Taken together, our results show that antigen targeting to CD8α+ DCs using DNA vaccines is a promising strategy to induce cellular and humoral responses and may be used in the development of more efficient dengue vaccines.

Go to:

Author Contributions

AZ and SB designed the experiments. AZ, FS, BA, HS, NF, NS, and MY conducted most of the experiments. AZ and SB analyzed the data. AZ and SB prepared the figures and wrote the manuscript. LF, DM, and DR contributed reagents. DR, LF, FS, NS, and MY revised the manuscript. All authors read and approved the final version of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Go to:


The authors would like to thank Danielle Chagas, Anderson Domingos Silva and Doroty Nunes da Silva for assistance in the animal facility, and Dr. Mauro Javier Cortéz Veliz for the use of the immunofluorescence microscope.

Go to:


Funding. The São Paulo Research Foundation (FAPESP, grant numbers 2013/11442-4, 2014/50631-0, 2014/17595-0, and 2014/15061-8), the Brazilian National Research Council (CNPq, grant number 472509/2011-0) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES, Finance Code 001) funded this research. AZ, FS, and BS received fellowships from FAPESP (2016/04477-4, 2015/18874-2, and 2015/16565-2, respectively). SB, DR, and LF are recipients of CNPq fellowships.

Go to:

Supplementary Material

The Supplementary Material for this article can be found online at:

Click here for additional data file.(1.7M, PDF)

Go to:


  1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. . The global distribution and burden of dengue. Nature (2013) 496:504–7. 10.1038/nature12060nature12060 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  2. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. (2007) 5:518–28. 10.1038/nrmicro1690 [PubMed] [CrossRef] [Google Scholar]
  3. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication, In: Knipe DM, Howley PM, editors. Fields Virology. 4th ed Philadelphia, PA: Lippincott Williams & Wilkins; (2001). p. 991–1042. [Google Scholar]
  4. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis. (2007) 30:329–40. 10.1016/j.cimid.2007.05.010 [PubMed] [CrossRef] [Google Scholar]
  5. Zhang ZS, Yan YS, Weng YW, Huang HL, Li SQ, He S, et al. . High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. J Virol Methods (2007) 143:125–31. 10.1016/j.jviromet.2007.02.012 [PubMed] [CrossRef] [Google Scholar]
  6. Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine (2010) 28:8085–94. 10.1016/j.vaccine.2010.10.004 [PubMed] [CrossRef] [Google Scholar]
  7. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol. (2001) 75:7769–73. 10.1128/JVI.75.16.7769-7773.2001 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  8. Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses (2011) 3:2374–95. 10.3390/v3122374 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  9. Poggianella M, Slon Campos JL, Chan KR, Tan HC, Bestagno M, Ooi EE, et al. . Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes. PLoS Negl Trop Dis. (2015) 9:e0003947. 10.1371/journal.pntd.0003947 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  10. Bukowski JF, Kurane I, Lai CJ, Bray M, Falgout B, Ennis FA. Dengue virus-specific cross-reactive CD8+human cytotoxic T lymphocytes. J Virol. (1989) 63:5086–91. [PMC free article] [PubMed] [Google Scholar]
  11. Kurane I, Meager A, Ennis FA. Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J Exp Med. (1989) 170:763–75. [PMC free article] [PubMed] [Google Scholar]
  12. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest. (2004) 113:946–51. 10.1172/JCI21512 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  13. Weiskopf D, Bangs DJ, Sidney J, Kolla RV, De Silva AD, de Silva AM, et al. . Dengue virus infection elicits highly polarized CX3CR1+cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci USA. (2015) 112:E4256–63. 10.1073/pnas.1505956112 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  14. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature (1998) 392 245–52. 10.1038/32588 [PubMed] [CrossRef] [Google Scholar]
  15. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med. (2003) 198:111–22. 10.1084/jem.20021542 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  16. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. (2013) 31:563–604. 10.1146/annurev-immunol-020711-074950 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  17. Inaba K, Swiggard WJ, Inaba M, Meltzer J, Mirza A, Sasagawa T, et al. . Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol. (1995) 163:148–56. [PubMed] [Google Scholar]
  18. Witmer-Pack MD, Swiggard WJ, Mirza A, Inaba K, Steinman RM. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II Expression in situ in lymphoid and nonlymphoid tissues Cell Immunol. (1995) 163:157–62. [PubMed] [Google Scholar]
  19. Guo M, Gong S, Maric S, Misulovin Z, Pack M, Mahnke K, et al. . A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol. (2000) 61:729–38. 10.1016/S0198-8859(00)00144-0 [PubMed] [CrossRef] [Google Scholar]
  20. Ebner S, Ehammer Z, Holzmann S, Schwingshackl P, Forstner M, Stoitzner P, et al. . Expression of C-type lectin receptors by subsets of dendritic cells in human skin. Int Immunol (2004) 16:877–87. 10.1093/intimm/dxh088 [PubMed] [CrossRef] [Google Scholar]
  21. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, et al. . The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol (2000) 151:673–84. 10.1083/jcb.151.3.673 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  22. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol. (2000) 164:2978–86. 10.4049/jimmunol.164.6.2978 [PubMed] [CrossRef] [Google Scholar]
  23. den Haan JM, Lehar SM, Bevan MJ. CD8+but not CD8 dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. (2000) 192:1685–96. 10.1084/jem.192.12.1685 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  24. Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, et al. . The CD8+dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med. (2002) 195:1289–302. 10.1084/jem.20020161 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  25. Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, Heath WR, et al. Epidermal viral immunity induced by CD8alpha+dendritic cells but not by Langerhans cells. Science (2003) 301:1925–8. 10.1126/science.1087576 [PubMed] [CrossRef] [Google Scholar]
  26. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. . In vivotargeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. (2004) 199:815–24. 10.1084/jem.20032220 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  27. Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, et al. . Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med. (2006) 203:599–606. 10.1084/jem.20051639 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  28. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, et al. . Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 315:107–11. 10.1126/science.1136080 [PubMed] [CrossRef] [Google Scholar]
  29. Do Y, Koh H, Park CG, Dudziak D, Seo P, Mehandru S, et al. . Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J Immunol. (2010) 40:2791–6. 10.1002/eji.201040511 [PubMed] [CrossRef] [Google Scholar]
  30. Henriques HR, Rampazo EV, Goncalves AJ, Vicentin EC, Amorim JH, Panatieri RH, et al. . Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge. PLoS Negl Trop Dis. (2013) 7:e2330. 10.1371/journal.pntd.0002330 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  31. Rampazo EV, Amorim KN, Yamamoto MM, Panatieri RH, Rodrigues MM, Boscardin SB. Antigen targeting to dendritic cells allows the identification of a CD4 T-cell epitope within an immunodominant trypanosoma cruzi antigen. PLoS ONE (2015) 10:e0117778. 10.1371/journal.pone.0117778 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  32. Amorim KN, Rampazo EV, Antonialli R, Yamamoto MM, Rodrigues MM, Soares IS, et al. . The presence of T cell epitopes is important for induction of antibody responses against antigens directed to DEC205+dendritic cells. Sci Rep. (2016) 6:39250. 10.1038/srep39250 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  33. Antonialli R, Sulczewski FB, Amorim K, Almeida BDS, Ferreira NS, Yamamoto MM, et al. . CpG Oligodeoxinucleotides and flagellin modulate the immune response to antigens targeted to CD8alpha(+) and CD8alpha(−) conventional dendritic cell subsets. Front Immunol. (2017) 8:1727. 10.3389/fimmu.2017.01727 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  34. Apostolico JS, Lunardelli VA, Yamamoto MM, Souza HF, Cunha-Neto E, Boscardin SB, et al. . Dendritic cell targeting effectively boosts T cell responses elicited by an HIV multiepitope DNA vaccine. Front Immunol. (2017) 8:101. 10.3389/fimmu.2017.00101 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  35. Rosa DS, Apostólico JS, Boscardin SB. DNA vaccines: how much have we accomplished in the last 25 years? J Vaccines Vaccin. (2015) 6:283 10.4172/2157-7560.1000283 [CrossRef] [Google Scholar]
  36. Demangel C, Zhou J, Choo AB, Shoebridge G, Halliday GM, Britton WJ. Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol Immunol. (2005) 42:979–85. 10.1016/j.molimm.2004.09.034 [PubMed] [CrossRef] [Google Scholar]
  37. Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG, Huang Y, et al. . The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest. (2008) 118:1427–36. 10.1172/JCI34224 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  38. Cao J, Jin Y, Li W, Zhang B, He Y, Liu H, et al. . DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice. BMC Immunol. (2013) 14:39. 10.1186/1471-2172-14-39 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  39. Chen BY, Zhou G, Li QL, Lu JS, Shi DY, Pang XB, et al. . Enhanced effects of DNA vaccine against botulinum neurotoxin serotype A by targeting antigen to dendritic cells. Immunol Lett. (2017) 190:118–24. 10.1016/j.imlet.2017.08.004 [PubMed] [CrossRef] [Google Scholar]
  40. Hua Y, Jiao YY, Ma Y, Peng XL, Fu YH, Zhang XJ, et al. . Enhanced humoral and CD8+T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells. Int Immunopharmacol. (2017) 46:62–9. 10.1016/j.intimp.2017.02.023 [PubMed] [CrossRef] [Google Scholar]
  41. Ngu LN, Nji NN, Ambada G, Ngoh AA, Njambe Priso GD, Tchadji JC, et al. . Dendritic cell targeted HIV-1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+T cells. Immun Inflamm Dis. (2018) 6:163–75. 10.1002/iid3.209 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  42. Ring S, Maas M, Nettelbeck DM, Enk AH, Mahnke K. Targeting of autoantigens to DEC205(+) dendritic cells in vivosuppresses experimental allergic encephalomyelitis in mice. J Immunol. (2013) 191:2938–47. 10.4049/jimmunol.1202592 [PubMed] [CrossRef] [Google Scholar]
  43. Maeda D, Batista MT, Pereira LR, de Jesus Cintra M, Amorim JH, Mathias-Santos C, et al. . Adjuvant-mediated epitope specificity and enhanced neutralizing activity of antibodies targeting dengue virus envelope protein. Front Immunol. (2017) 8:1175. 10.3389/fimmu.2017.01175 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  44. Lambeth CR, White LJ, Johnston RE, de Silva AM. Flow cytometry-based assay for titrating dengue virus. J Clin Microbiol. (2005) 43:3267–72. 10.1128/JCM.43.7.3267-3272.2005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  45. Medina F, Medina JF, Colon C, Vergne E, Santiago GA, Munoz-Jordan JL. Dengue virus: isolation, propagation, quantification, and storage. Curr Protoc Microbiol (2012). Chapter 15, Unit 15D.12. 10.1002/9780471729259.mc15d02s27 [PubMed] [CrossRef] [Google Scholar]
  46. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. . The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. (2010) 8:271–83. 10.1016/j.chom.2010.08.007 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  47. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, et al. . The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. (2010) 6:e1000823. 10.1371/journal.ppat.1000823 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  48. WHO (Ed.). Global Strategy for Dengue Prevention and Control 2012-2020. France: WHO Library Cataloguing-in-Publication Data; (2012). [Google Scholar]
  49. Vannice KS, Durbin A, Hombach J. Status of vaccine research and development of vaccines for dengue. Vaccine (2016) 34:2934–8. 10.1016/j.vaccine.2015.12.073 [PubMed] [CrossRef] [Google Scholar]
  50. Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, et al. . Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. (2018) 19:e31–8. 10.1016/S1473-3099(18)30494-8 [PubMed] [CrossRef] [Google Scholar]
  51. Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, Soares H, et al. . Intensified and protective CD4+T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med. (2006) 203:607–17. 10.1084/jem.20052005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  52. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, et al. . The microbial mimic poly IC induces durable and protective CD4+T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA (2008) 105:2574–9. 10.1073/pnas.0711976105 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  53. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. (2011) 23:421–9. 10.1016/j.coi.2011.03.008 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  54. Sales NS, Silva JR, Aps L, Silva MO, Porchia B, Ferreira LCS, et al. . In vivoelectroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8(+) T cells. Vaccine (2017) 35:7240–9. 10.1016/j.vaccine.2017.11.011 [PubMed] [CrossRef] [Google Scholar]
  55. Coconi-Linares N, Ortega-Davila E, Lopez-Gonzalez M, Garcia-Machorro J, Garcia-Cordero J, Steinman RM, et al. . Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice. Vaccine (2013) 31:2366–71. 10.1016/j.vaccine.2013.03.009 [PubMed] [CrossRef] [Google Scholar]
  56. Tenbusch M, Ignatius R, Nchinda G, Trumpfheller C, Salazar AM, Topfer K, et al. . Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques. PLoS ONE (2012) 7:e39038. 10.1371/journal.pone.0039038 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  57. Yu D, Liu H, Shi S, Dong L, Wang H, Wu N, et al. . A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice. Immunol Lett. (2015) 168:293–9. 10.1016/j.imlet.2015.10.007 [PubMed] [CrossRef] [Google Scholar]
  58. Niezold T, Storcksdieck Genannt Bonsmann M, Maaske A, Temchura V, Heinecke V, Hannaman D, et al. DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance? Immunology (2015) 145:519–33. 10.1111/imm.12467 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  59. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, et al. . Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 81:12816–26. 10.1128/JVI.00432-07 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  60. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. . Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. (2010) 84:9227–39. 10.1128/JVI.01087-10 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  61. Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis. (2013) 7:e2274. 10.1371/journal.pntd.0002274 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  62. Alexander MR, Ringe R, Sanders RW, Voss JE, Moore JP, Klasse PJ. What do chaotrope-based avidity assays for antibodies to HIV-1 envelope glycoproteins measure? J Virol. (2015) 89:5981–95. 10.1128/JVI.00320-15 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  63. Valdes I, Gil L, Romero Y, Castro J, Puente P, Lazo L, et al. . The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin Vaccine Immunol. (2011) 18:455–9. 10.1128/CVI.00382-10 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  64. Soares H, Waechter H, Glaichenhaus N, Mougneau E, Yagita H, Mizenina O, et al. . A subset of dendritic cells induces CD4+T cells to produce IFN-gamma by an IL-12-independent but CD70 dependent mechanism in vivo. J Exp Med. (2007) 204:1095–106. 10.1084/jem.20070176 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  65. Do Y, Park CG, Kang YS, Park SH, Lynch RM, Lee H, et al. . Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur J Immunol. (2008) 38:20–9. 10.1002/eji.200737799 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  66. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. . Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. (2007) 13:843–50. 10.1038/nm1592 [PubMed] [CrossRef] [Google Scholar]
  67. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. . Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol. (2005) 79:14169–78. 10.1128/JVI.79.22.14169-14178.2005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  68. Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, Martin JN, et al. . HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS (2010) 24:1095–105. 10.1097/QAD.0b013e3283377a1e [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  69. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, et al. . Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. (2011) 203:1282–91. 10.1093/infdis/jir012jir012 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  70. Lindow JC, Borochoff-Porte N, Durbin AP, Whitehead SS, Fimlaid KA, Bunn JY, et al. . Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl Trop Dis. (2012) 6:e1742. 10.1371/journal.pntd.0001742 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  71. Tenbusch M, Nchinda G, Storcksdieck genannt Bonsmann M, Temchura V, Uberla K. Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response. Int Immunol. (2013) 25:247–58. 10.1093/intimm/dxs112dxs112 [PubMed] [CrossRef] [Google Scholar]
  72. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. . Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. (2001) 194:769–79. 10.1084/jem.194.6.769 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  73. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, et al. . DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 448:501–5. 10.1038/nature06013 [PubMed] [CrossRef] [Google Scholar]
  74. Li S, Peng L, Zhao W, Zhong H, Zhang F, Yan Z, et al. . Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine (2011) 29:3695–702. 10.1016/j.vaccine.2011.03.002 [PubMed] [CrossRef] [Google Scholar]
  75. Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J, Cerpas C, et al. . Global Assessment of Dengue Virus-Specific CD4(+) T cell responses in dengue-endemic areas. Front Immunol. (2017) 8:1309. 10.3389/fimmu.2017.01309 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  76. Weiskopf D, Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, et al. . HLA-DRB1 alleles are associated with different magnitudes of dengue virus-specific CD4+T-Cell responses. J Infect Dis. (2016) 214:1117–24. 10.1093/infdis/jiw309 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  77. Roehrig JT, Risi PA, Brubaker JR, Hunt AR, Beaty BJ, Trent DW, et al. . T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology (1994) 198:31–8. 10.1006/viro.1994.1005 [PubMed] [CrossRef] [Google Scholar]
  78. Kurane I, Innis BL, Nisalak A, Hoke C, Nimmannitya S, Meager A, et al. . Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production. J Clin Invest. (1989) 83:506–13. 10.1172/JCI113911 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  79. Green S, Kurane I, Edelman R, Tacket CO, Eckels KH, Vaughn DW, et al. . Dengue virus-specific human CD4+T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination. J Virol. (1993) 67:5962–7. [PMC free article] [PubMed] [Google Scholar]
  80. Goncalves AJ, Oliveira ER, Costa SM, Paes MV, Silva JF, Azevedo AS, et al. . Cooperation between CD4+T Cells and humoral immunity is critical for protection against dengue using a DNA vaccine based on the NS1 antigen. PLoS Negl Trop Dis. (2015) 9:e0004277. 10.1371/journal.pntd.0004277 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  81. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, et al. . CD4+T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol. (2010) 185:5405–16. 10.4049/jimmunol.1001709 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  82. Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol. (2001) 166:5327–30. 10.4049/jimmunol.166.9.5327 [PubMed] [CrossRef] [Google Scholar]
  83. den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8+and CD8 dendritic cells in vivo. J Exp Med. (2002) 196:817–27. 10.1084/jem.20020295 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  84. Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, et al. . Differential targeting of viral components by CD4+versus CD8+ T lymphocytes in dengue virus infection. J Virol. (2013) 87:2693–706. 10.1128/JVI.02675-12 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA


Dengue antigens

Leave a comment

All comments are moderated before being published